GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thalys Medical Technology Group Corp (SHSE:603716) » Definitions » Capex-to-Revenue

Thalys Medical Technology Group (SHSE:603716) Capex-to-Revenue : 0.02 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Thalys Medical Technology Group Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Thalys Medical Technology Group's Capital Expenditure for the three months ended in Sep. 2024 was ¥-8.66 Mil. Its Revenue for the three months ended in Sep. 2024 was ¥444.42 Mil.

Hence, Thalys Medical Technology Group's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.02.


Thalys Medical Technology Group Capex-to-Revenue Historical Data

The historical data trend for Thalys Medical Technology Group's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thalys Medical Technology Group Capex-to-Revenue Chart

Thalys Medical Technology Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.06 0.02 0.02 0.02

Thalys Medical Technology Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.04 0.01 - 0.02

Competitive Comparison of Thalys Medical Technology Group's Capex-to-Revenue

For the Diagnostics & Research subindustry, Thalys Medical Technology Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thalys Medical Technology Group's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thalys Medical Technology Group's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Thalys Medical Technology Group's Capex-to-Revenue falls into.



Thalys Medical Technology Group Capex-to-Revenue Calculation

Thalys Medical Technology Group's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-40.825) / 2006.134
=0.02

Thalys Medical Technology Group's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-8.658) / 444.424
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thalys Medical Technology Group  (SHSE:603716) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Thalys Medical Technology Group Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Thalys Medical Technology Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Thalys Medical Technology Group Business Description

Traded in Other Exchanges
N/A
Address
1310 Jinshan Avenue, Dongxihu District, Hubei Province, Wuhan, CHN, 430040
Thalys Medical Technology Group Corp is engaged in intensive sales business, pure sales, and research and development, production and sales of independent in vitro diagnostic products.
Executives
Wang Jun Ming senior management
Wang Zheng senior management
Wang Wen Bin senior management
Liu Wen Hao Director
Huang Yong Xi senior management
Lei Xian Kun Director
Fan Li Director
Liu Yuan senior management
Wan Li Bo senior management
Wen Wei Director
Chou Jian senior management
Song Yu Director

Thalys Medical Technology Group Headlines

No Headlines